Literature DB >> 26582885

Single-Dose Universal Hepatitis A Immunization in Argentina: Low Viral Circulation and High Persistence of Protective Antibodies Up to 4 Years.

C Vizzotti1, J González2, A Rearte1, A Urueña1, M Pérez Carrega1, R Calli3, A Gentile4, A Uboldi5, M Ramonet6, M Cañero-Velasco7, M Diosque1.   

Abstract

BACKGROUND: Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children aged 12 months in 2005. Between 2005 and 2011, a dramatic decline was observed in HAV infection rates, fulminant hepatitis, and liver transplantation. This study assessed current viral circulation and estimated protective antibody persistence 4 years after vaccination.
METHODS: Prevalence of prevaccination anti-HAV antibodies in 12-month-old children was evaluated as an indirect estimation of viral circulation (Group A). Seroprevalence was also measured in 5-year-old children who received 1 dose of HAV vaccine at 1 year of age (Group B). Blood samples were tested for immunoglobulin (Ig)G anti-HAV antibodies (seroprotection = ≥10 mIU/mL). All Group A-positive samples were tested for IgM anti-HAV antibodies to identify recent infections. Logistic regression analysis was done to evaluate associations between demographic and socioeconomic variables and seroprotection.
RESULTS: Of 433 children from Group A, 29.5% (95% confidence interval [CI], 25.2-33.8) were positive for IgG anti-HAV antibodies with a geometric mean concentration (GMC) of 6.17 mIU/mL (95% CI, 5.33-7.15 mIU/mL); all IgM anti-HAV were negative. From 1139 in Group B, 93% (95% CI, 91.7-94.6) maintained seroprotection with a GMC of 97.96 mIU/mL (95% CI, 89.21-107.57 mIU/mL). Kindergarten attendance was associated with seroprotection in Group B (odds ratio [OR], 2.0; 95% CI, 1.26-3.3). In contrast, high maternal educational level was associated with a lack of seroprotection in this group (OR, .26; 95% CI, .09-.8).
CONCLUSIONS: Single-dose, universal hepatitis A immunization in infants resulted in low HAV circulation and persistent immunologic protection up to 4 years in Argentina. Variables associated with presence or absence of seroprotection in vaccinated children could be related to differences in hygiene habits in settings with residual viral circulation.
© The Author 2014. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Argentina; hepatitis A; immunogenicity; single-dose vaccination; viral circulation

Mesh:

Substances:

Year:  2014        PMID: 26582885     DOI: 10.1093/jpids/piu068

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  5 in total

1.  Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine.

Authors:  Zhilun Zhang; Xiangjun Zhu; Yuansheng Hu; Miao Liang; Jin Sun; Yufei Song; Qi Yang; Haiquan Ji; Gang Zeng; Lifei Song; Jiangting Chen
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 2.  Immunization against Hepatitis A.

Authors:  Daniel Shouval
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

3.  Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina.

Authors:  Carlos Espul; Laura Benedetti; Mariela Linares; Hector Cuello; Ivana Lo Castro; Yaël Thollot; Anvar Rasuli
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

Review 4.  Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Authors:  Christian Herzog; Koen Van Herck; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

5.  Universal Single-Dose Vaccination against Hepatitis A in Children in a Region of High Endemicity.

Authors:  Mikhail I Mikhailov; Maria A Lopatukhina; Fedor A Asadi Mobarhan; Lyudmila Yu Ilchenko; Tatyana V Kozhanova; Olga V Isaeva; Anastasiya A Karlsen; Ilya A Potemkin; Vera S Kichatova; Anna A Saryglar; Natalia D Oorzhak; Karen K Kyuregyan
Journal:  Vaccines (Basel)       Date:  2020-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.